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tasis was 10.9 ± 8.9 months. The percentages of patients receiving at least one of these 
therapies increased from 10.5% in 2005 to 74% in 2008. Sunitinib use showed consis-
tent increase from 0% in 2005 to 50% in 2008. Sorafenib with zero use in 2005 
increased to 25% in 2006 but decreased thereafter to 11.7% in 2008. Interferon-alpha 
(range: 5–8%) and bevacizumab (range: 2–4%) use remained relatively stable during 
the observation period, whereas interleukin-2 and temsirolimus was used rarely (≤1%) 
and everolimus not used at all. CONCLUSIONS: Pharmacologic agents were increas-
ingly used to treat mRCC patients in recent years. Targeted therapies have become the 
main modality of treatment, with sunitinib accounting for most of the growth.
PCN153
TREATMENT PATTERNS OF MEXICAN ONCOLOGISTS IN FIVE 
DIFFERENT MALIGNANCIES: A SURVEY
Tenorio-Téllez LMC1, Vargas-Valencia J2, Martínez-Fonseca J2, Sotelo-Guzmán M2, 
Mould-Quevedo JF3
1Instituto Nacional de Cancerología, Mexico City, Mexico, Mexico, 2Econopharma Consulting 
S. A. de C. V., Mexico City, Mexico, Mexico, 3Pﬁzer S.A. de C.V., México City, Mexico
OBJECTIVES: There is no evidence about real medical practice in oncology in 
Mexico. The objective of this study was to explore current medical practices of 
Mexican oncologists in the management of ﬁve malignancies: breast, non-small cell 
lung (NSCL), colon, rectum and kidney cancer. METHODS: A speciﬁc instrument for 
these malignancies was designed, validated and applied to Mexican oncologists. Infor-
mation requested reﬂects stage-speciﬁc treatment and disease management, including 
surgery and drugs uses, as well as frequency of prescription, discontinuation and 
factors that determines them in public and private health care institutions, between 
January-April 2009. RESULTS: 30 oncologists were included: 63.3% from Instituto 
Mexicano del Seguro Social and 20.0% from Instituto Nacional de Cancerología. 
73.3% of all oncologists have public and private practices. Tamoxiphen (adjuvant 
hormonoterapy) and 5-ﬂuoroacil/epirubicin/cyclophosphamide (adjuvant, neoadju-
vant and palliative chemotherapy) are the most frequently drug schemes used in breast 
cancer, with no differences between public and private practices(p < 0.05). At least 
85.0% of NSCL cancer cases are diagnosed in IIIA and IV stages; combination che-
motherapy (platinum/etoposide) is highly prescribed in NSCL cancer patients undergo-
ing radiotherapy or non-resectable disease. Colon cancer is diagnosed in stages 
III(58.0%) and IV (14.0%); 20.0% of colon cancer patients undergoes surgery (left 
or right hemicolectomy). Drug availability and medical guidelines recommendations 
drive prescription to treat colon cancer. Surgery in rectum cancer is applied at stages 
IIB, IIIA and IIIB (17.6%, 20.0% and 16.9%, respectively). Rectum cancer presents 
as non-resectable disease in 60.0% of cases in stage IV. Drugs used to treat metastatic 
renal cells cancer are interferon-α (80.0%) and sunitinib(19.0%), prescription is 
driven by drug availability and efﬁcacy, respectively. Discontinuation rate of inter-
feron-α due adverse event was 90.0%. CONCLUSIONS: Knowledge of oncology 
current medical practice provides a basis for evaluation, as well as supports decision 
making process and the generation of new strategies for policy makers.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common form of cancer in 
men and women in West Virginia. Hospitalization followed by surgical resection is 
the standard curative treatment. The aim of this study is to examine colorectal cancer 
hospitalizations and common comorbidities and evaluate associated outcomes during 
2003–2007 in West Virginia. METHODS: Data from the Healthcare Cost and Utiliza-
tion Project (HCUP), State Inpatient Database were investigated. Comorbidities were 
identiﬁed using comorbidity software provided by HCUP. Descriptive statistics for 
hospitalizations with a primary or secondary diagnosis of CRC were tabulated. Mul-
tivariate regressions were used to compare for differences in the outcomes including 
length of stay, total charges, and in-hospital deaths. RESULTS: There were 6919 
admissions with a primary or secondary diagnosis of CRC of which 27.4% were 
emergency admissions. The most common comorbidity was diabetes (18.5%), fol-
lowed by COPD and hypertension (both 3.7%). Volume depletion disorder (3.5%) 
followed by pneumonia (2.4%) and malignant neoplasm of the liver (2.3%) were the 
most common primary diagnoses seen when CRC was the secondary diagnosis. Mean 
length of stay was signiﬁcantly higher for admissions with a primary diagnosis (9.2 
days versus 4.8 days, p < 0.001). Mean total charges were also higher for primary 
diagnosis (28,618.94 USD versus 12,195.22 USD, p < 0.001). For the 356 (5.1%) 
in-hospital deaths, emergency admissions had odds ratio (OR) of 2.50 (95% CI, 
2.01–3.10), and primary diagnosis of CRC had OR of 1.64 (95% CI, 1.30–2.08). 
Admissions with comorbid diabetes formed 12.6% (45) of patients who died in the 
hospital. CONCLUSIONS: Signiﬁcant resources are consumed by CRC hospital 
admissions. A large percentage of CRC hospitalizations are emergency admissions 
indicating advanced disease and possibly failure of timely screening. Diabetes was the 
most common comorbid condition and further investigation in diabetics is needed to 
check screening behavior and access to screening centers.
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OBJECTIVES: Triple negative (TN) breast cancer (BC), a subtype of BC characterized 
by its unique molecular proﬁle and aggressive clinical behavior, lacks satisfactory 
standard therapies. Little is known about how patients with TNBC were treated in 
community practice. This study was conducted to identify treatment patterns of ﬁrst-
line chemotherapy (CT) of TNBC using data from community practices. METHODS: 
Analyses were conducted using the Georgia Cancer Specialist Database (GCSD 2003–
2008) and the International Oncology Network’s Treatment and Outcomes Database 
(ION 2003–2008). In both data, patients with stage IV TNBC were selected and fol-
lowed for up to one year since initial diagnosis. The ﬁrst-line CT was identiﬁed if 1) 
the ﬁrst drug was initiated within 120 days following the initial BC diagnosis; 2) other 
combination drugs be started within 30 days of the ﬁrst drug. RESULTS: The study 
included 30 and 35 patients from GCSD and ION, respectively. In GCSD sample, 14 
patients (47%) were treated with monotherapy, capecitabine and taxanes being domi-
nant (50% and 43%, respectively); 16 patients treated with combination therapy, with 
carboplatin/gemcitabine+paclitaxel (C/G+P) and cyclophosphomide+doxorubicin 
(CP+DOX) most frequently used regimens or backbone therapies (31% for each). 
Other drugs used in combination included docetaxel, bevacizumab, 5-FU and albu-
min-bound P. Similar patterns were found in ION sample with some deviations: 20 
patients (57%) treated with monotherapy, taxanes being dominant (70%); 15 patients 
treated with combination therapy, C/G+P and CP+DOX/+epirubicin were the most 
frequently used regimens or backbone therapies (33% for each). Other drugs used in 
combination included docetaxel, 5-FU, bevacizumab, lapatinib and methotrexate. 
CONCLUSIONS: It appears that taxanes/capecitabine, and C/G+P or CP+DOX were 
mostly used monotherapy and combination therapy, respectively, for stage IV TNBC. 
The patterns are rather diverse than convergent, reﬂecting lack of standard therapy 
for TNBC. Data from other community settings are needed to conﬁrm these results.
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BACKGROUND: Ascertainment of vital status is critical to studies in many disease 
areas especially in oncology. Two commonly used sources for mortality are SSDMF 
and NDI, with NDI considered the gold standard. Limitations identiﬁed in previous 
studies are under-ascertainment associated with the former; time lag (1–2 years) and 
higher cost associated with the latter. OBJECTIVES: To compare ascertainment of 
vital status by consolidating mortality data from SSDMF and NDI vs. either source 
alone. METHODS: Patient identiﬁers for a cohort of 3761 cancer patients from a 
large US claims database were submitted to SSDMF (cutoff February 2009) and NDI 
(cutoff December 2007) to obtain vital status. Matching to SSDMF utilized SSN alone 
or a combination of last name, ﬁrst name and birthdate. Matching to NDI utilized 
combinations of SSN and/or patient name, birthdate, and state of residence. For 
patients with a death date found in NDI, a variable indicating a true or false match 
was provided by NDI based on the probabilistic score. We derived the death date via 
a stepwise approach by utilizing all match results from either source. RESULTS: Of 
3761 patients, SSDMF returned a match for 901 (24%) patients using SSN alone, and 
1088 (29%) patients using the combination. From the NDI, 946 (25%) patients had 
a “true” match, 1408 (37%) had a “false” match, and remainder were considered 
alive. Comparing SSDMF and NDI results utilizing both true and false NDI matches, 
we derived death dates for 1326 patients, which is 47% and 40% more compared to 
SSDMF match by SSN alone or NDI true match, respectively. Eight patients had claims 
following death date and were considered false matches. CONCLUSIONS: Utilizing 
all match results from SSDMF and NDI identiﬁed signiﬁcantly more deceased patients 
compared to either source alone. Misclassiﬁcation of living patients as deceased 
appears minimal as veriﬁed by claims.
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Febrile neutropenia (FN) is a condition that develops in cancer patients treated with 
myelosuppressive chemotherapy characterized by fever and very low neutrophil 
counts, in general signaling infection. Utilizing claims data can provide a real-world 
perspective on the epidemiology, treatment, outcomes, and costs associated with FN 
in cancer patients. However, identifying true cases of FN in claims data can be prob-
